OncologyPancreatic cancer pill extends survival across RAS types at ESMO
New RASolute 302 subgroup data at ESMO 2026 show daraxonrasib beat chemotherapy on survival across RAS mutation types, though several smaller groups remain statistically uncertain.
23 October 2026